CAR-T Therapy Shifts Upstream in Multiple Myeloma Treatment
Event summary
- CAR-T therapy is projected to rise from 14% to 24% share in second-line multiple myeloma treatment within six months.
- 73% of surveyed U.S. oncologists and hematologists believe CAR-T will become a first-line standard of care.
- CAR-T share in third-line treatment is expected to grow from 23% to 28% over the next six months.
- Physicians remain uncertain about the optimal sequencing of CAR-T with bispecific antibodies.
The big picture
The multiple myeloma treatment landscape is undergoing a significant shift as CAR-T therapy moves upstream, challenging traditional sequencing conventions. This evolution reflects growing physician confidence in CAR-T's long-term efficacy and operational readiness for broader adoption. The dynamic underscores the rapid pace of innovation in oncology, where therapeutic options are expanding and reshaping treatment paradigms.
What we're watching
- Treatment Sequencing
- How physicians will resolve the tension between CAR-T and bispecific antibodies in treatment sequencing.
- Adoption Pace
- The pace at which CAR-T therapy will be integrated into earlier lines of multiple myeloma treatment.
- Competitive Dynamics
- Whether CAR-T's growth will continue to erode the market share of traditional backbone regimens.
Related topics